Figure 7

NF90 and IRF3/9 levels decline during COVID-19 infection. (A,B) NF90 RIP analysis in Jurkat cells and PBMCs; NF90 or IgG antibodies were used for RIP from Jurkat lysates (A) or PBMC lysates (B), and the presence of NF90 in the IP was assessed by Western blot analysis (A). The levels of target IRF3 and IRF9 mRNAs in the RIP samples were measured by RT-qPCR analysis and the levels of enrichment of these mRNAs in NF90 IP relative to IgG IP were calculated after normalization to ACTB mRNA levels in each IP. (C) In PBMCs purified from healthy control (CTRL) and from patients (PZ) infected with SARS-CoV-2, the levels of NF90, IRF3, and IRF9 were assessed by Western blot analysis (left panel) and subsequently quantified using ImageJ (right panel). The levels of ACTB were included to monitor loading in Western blots analyses. Data are the means and standard deviation (+ SD) from at least three independent experiments. *, P < 0.05; ***, P < 0.005.